Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...

With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.

MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...

Too old and too sick for a heart transplant, Arvid Herrman was given a choice: Have a mechanical pump implanted in his heart, potentially keeping him alive for several years, or do nothing and almost ...

A six-month analysis of the pivotal MOMENTUM 3 trial found that patients implanted with the new HeartMate 3 left ventricular assist system (LVAS) had fewer adverse clotting and bleeding events than ...

PLEASANTON, Calif., Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced the first ever HeartMate 3™ implant ...

Richard Lord had congestive heart failure so advanced that he'd have shortness of breath from ­sitting on the couch or laying in bed. Doctors said his weakened heart would only keep him alive for ...

Thousands of patients experiencing heart failure may have increased life expectancy when using Abbott Medical Devices HeartMate 3 heart pump, according to recently released data from the company’s ...

Patients with the HeartMate 3 had fewer of these adverse events - 28 percent of patients versus 38 percent for those on HeartMate II. Those on HeartMate 3 tended to have bleeding events, which are ...

New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for ...

ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...